Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Vimalanand S. Prabhu; Oliver A. Cornely; Yoav Golan; Erik R. Dubberke; Sebastian M. Heimann; Mary E. Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella

doi:10.1093/cid/cix523

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Vimalanand S. Prabhu, Oliver A. Cornely, Yoav Golan, Erik R. Dubberke, Sebastian M. Heimann, Mary E. Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

Original language	English
Pages (from-to)	1218-1221
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	65
Issue number	7
DOIs	https://doi.org/10.1093/cid/cix523
State	Published - 1 Oct 2017
Externally published	Yes

Keywords

C. difficile infection
bezlotoxumab
hospital readmissions
recurrence

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cix523

Cite this

Prabhu, V. S., Cornely, O. A., Golan, Y., Dubberke, E. R., Heimann, S. M., Hanson, M. E., Liao, J., Pedley, A., Dorr, M. B., & Marcella, S. (2017). Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection. Clinical Infectious Diseases, 65(7), 1218-1221. https://doi.org/10.1093/cid/cix523

@article{ac1e400324824f6381ae0d5351d9fa16,

title = "Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection",

abstract = "We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).",

keywords = "C. difficile infection, bezlotoxumab, hospital readmissions, recurrence",

author = "Prabhu, {Vimalanand S.} and Cornely, {Oliver A.} and Yoav Golan and Dubberke, {Erik R.} and Heimann, {Sebastian M.} and Hanson, {Mary E.} and Jane Liao and Alison Pedley and Dorr, {Mary Beth} and Stephen Marcella",

note = "Funding Information: Financial support. This work was supported by Merck & Co., Inc., Kenilworth, NJ. Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/cid/cix523",

language = "English",

volume = "65",

pages = "1218--1221",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

AU - Prabhu, Vimalanand S.

AU - Cornely, Oliver A.

AU - Golan, Yoav

AU - Dubberke, Erik R.

AU - Heimann, Sebastian M.

AU - Hanson, Mary E.

AU - Liao, Jane

AU - Pedley, Alison

AU - Dorr, Mary Beth

AU - Marcella, Stephen

N1 - Funding Information: Financial support. This work was supported by Merck & Co., Inc., Kenilworth, NJ. Publisher Copyright: © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

AB - We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

KW - C. difficile infection

KW - bezlotoxumab

KW - hospital readmissions

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85030669720&partnerID=8YFLogxK

U2 - 10.1093/cid/cix523

DO - 10.1093/cid/cix523

M3 - Article

C2 - 30060024

AN - SCOPUS:85030669720

SN - 1058-4838

VL - 65

SP - 1218

EP - 1221

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this